SynergyFinder 2.0: visual analytics of multi-drug combination synergies
By Aleksandr Ianevski, Anil K. Giri, Tero Aittokallio. Nucleic Acids Res., 2020
728 citations recorded by the source corpus.
Abstract SynergyFinder (https://synergyfinder.fimm.fi) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data. Since its first release in 2017, SynergyFinder has become a widely used web-tool both for the discovery of novel synergistic drug combinations in pre-clinical model systems (e.g. cell lines or primary patient-derived cells), and for better understanding of mechanisms of combination treatment efficacy or resistance. Here, we describe the latest version of SynergyFinder (release 2.0), which has extensively been upgraded through the addition of novel features supporting especially higher-order combination data analytics and exploratory visualization of multi-drug synergy patterns, along with automated outlier detection procedure, extended curve-fitting functionality and statistical analysis of replicate measurements. A number of additional improvements were also implemented based on the user requests, including new visualization and export options, updated user interface, as well as enhanced stability and performance of the web-tool. With these improvements, SynergyFinder 2.0 is expected to greatly extend its potential applications in various areas of multi-drug combinatorial screening and precision medicine.
Subfields: Biomedical Engineering, Biophysics, Computational Theory and Mathematics
View Paper: https://www.semanticscholar.org/paper/82e55d62a1012e4d8f776013656dd69d3f4bedde
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biophysics
In Computational Theory and Mathematics
Citations in the corpus
- SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets (2022, methodology): “More recently, the SynergyFinder2 tool [14] has been developed, which extends to three-drug combinations.”